Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog
- PMID: 4056487
- DOI: 10.1089/jir.1985.5.403
Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog
Abstract
The pharmacokinetics of recombinant leukocyte A interferon (rIFN-alpha A) were studied following intravenous (i.v.) bolus, 60 min (i.v. inf.) infusion, intramuscular (i.m.), subcutaneous (s.c.), and oral (p.o.) administrations to 15 male beagle dogs. Each animal received at least one 3 X 10(6) units/kg dose of rIFN-alpha A by one of the five routes and/or modes of administration. Blood samples were collected and the serum was separated and analyzed for rIFN-alpha A concentrations by an enzyme immunoassay, ELISA. There were no measurable rIFN-alpha A concentrations (less than 0.020 ng/ml) following oral administration. In general serum rIFN-alpha A concentrations exceeded 100 ng/ml following i.v. bolus and infusion doses then declined rapidly in a biphasic manner. The volume of distribution at steady state Vdss ranged from 0.14 to 0.21 liters/kg after i.v. infusion. Total body serum clearance (ClB) ranged from 14.6 to 23.9 ml/min, which is about 50% the estimated inulin clearance in dogs. The harmonic mean elimination half-lives ranged from 4.5 to 9.5 h. A prolonged absorption profile was seen following i.m. and s.c. administrations and the systemic bioavailability for both routes was 42% when compared with the i.v. infusion. These appear to be the first pharmacokinetic profiles of rIFN-alpha A reported in the dog.
Similar articles
-
Pharmacokinetics of recombinant alpha A interferon following I.V. infusion and bolus, I.M., and P.O. administrations to African green monkeys.J Interferon Res. 1984 Summer;4(3):399-409. doi: 10.1089/jir.1984.4.399. J Interferon Res. 1984. PMID: 6491397
-
Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection.Clin Pharmacol Ther. 1984 May;35(5):722-7. doi: 10.1038/clpt.1984.101. Clin Pharmacol Ther. 1984. PMID: 6713784
-
Pharmacokinetics of recombinant human interferon-gamma in the rhesus monkey after intravenous, intramuscular, and subcutaneous administration.J Biol Response Mod. 1988 Apr;7(2):115-22. J Biol Response Mod. 1988. PMID: 3129541
-
Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration.Clin Pharmacol Ther. 1985 Jan;37(1):85-8. doi: 10.1038/clpt.1985.16. Clin Pharmacol Ther. 1985. PMID: 3965239
-
Pharmacokinetics of human recombinant interferon-alpha I after i.v. infusion and im injection in African green monkeys.J Interferon Res. 1988 Aug;8(4):427-32. doi: 10.1089/jir.1988.8.427. J Interferon Res. 1988. PMID: 3171243
Cited by
-
Oromucosal Administration of Interferon to Humans.Pharmaceuticals (Basel). 2010 Jan 28;3(2):323-344. doi: 10.3390/ph3020323. Pharmaceuticals (Basel). 2010. PMID: 27713254 Free PMC article. Review.
-
Antinociceptive activity of Stephanolepis hispidus skin aqueous extract depends partly on opioid system activation.Mar Drugs. 2013 Apr 10;11(4):1221-34. doi: 10.3390/md11041221. Mar Drugs. 2013. PMID: 23574984 Free PMC article.
-
Ingested Type I Interferon-State of the Art as Treatment for Autoimmunity Part 2.Pharmaceuticals (Basel). 2010 Apr 14;3(4):1108-1121. doi: 10.3390/ph3041108. Pharmaceuticals (Basel). 2010. PMID: 27713291 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources